White Blood Cells (WBCs) are essential. The market for WBC stimulating drugs is $8B/yr. WBC Labs has the next generation of WBC drugs.
WBCs stimulants are used in patients after chemotherapy or before transplant. Nevertheless patients too often develop infections, fevers or even fatal sepsis. The drugs from WBC Labs are conservatively targeted to increase the effectiveness of current drugs but should, in many cases, replace them. In addition there is major government interest in stockpiling WBC stimulating drugs to protect the public from biologic and radiation attack.